Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
      • All Events
      • COVID-19
      • Diabetes
      • Immunology
      • Neuroscience
      • Oncology
      • Cardiovascular
      • COVID-19
      • Diabetes
      • Immunology
      • Men's Health
      • Neuroscience
      • Oncology
  • Medical Education
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Taltz (ixekizumab) injection Right
  4. What is the incidence of hypersensitivity reactions with Taltz® (ixekizumab) in pediatric patients?
Search Taltz (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Taltz ® (ixekizumab) injection

80 mg/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

What is the incidence of hypersensitivity reactions with Taltz® (ixekizumab) in pediatric patients?

Ixekizumab is contraindicated in patients with known serious hypersensitivity to ixekizumab or to any of the excipients. In the all exposure population of IXORA-PEDS, 20 (10.2%) patients reported a nonanaphylactic allergic reaction/hypersensitivity TEAE.

US_cFAQ_IXE359_HYPERSENSITIVITY_REACTION_PEDS
US_cFAQ_IXE359_HYPERSENSITIVITY_REACTION_PEDS
en-US

Hypersensitivity-Related Label Information

IXORA-PEDS was a multicenter, randomized, double-blind, placebo-controlled phase 3 study designed to evaluate the efficacy and safety of ixekizumab in pediatric patients aged 6 to <18 years with moderate-to-severe plaque psoriasis.1,2

Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the ixekizumab group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in postmarketing use with ixekizumab. If a serious hypersensitivity reaction occurs, discontinue ixekizumab immediately and initiate appropriate therapy.3

Ixekizumab is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.3

Allergic Reaction/Hypersensitivity Treatment-Emergent Adverse Events in IXORA-PEDS

IXORA-PEDS: Allergic Reaction/Hypersensitivity Treatment-Emergent Adverse Events in the Double-Blind Treatment Period and Combined Treatment Periods provides a summary of allergic reaction/hypersensitivity treatment-emergent adverse events (TEAEs). The study reported no TEAEs of potential anaphylaxis.2

In the double-blind treatment period of IXORA-PEDS, 6 (5.2%) ixekizumab-treated patients and 1 (1.8%) patient in the placebo group reported an allergic reaction/hypersensitivity TEAE.1 No severe or serious allergic reaction/hypersensitivity adverse events (AEs) were reported. No patients discontinued study drug because of an allergic reaction/hypersensitivity AE.4

In the all ixekizumab exposure population through the 108-week final database lock, 20 (10.2%) patients reported a total of 22 allergic reaction/hypersensitivity TEAEs corresponding to an incidence rate of 5.8 per 100 patient-years of exposure. No allergic reaction/hypersensitivity serious AEs were reported. No patients discontinued study treatment because of an allergic reaction/hypersensitivity AE.2,4

Across 17 adult psoriasis trials (N=6892, accounting for 18,025.7 patient-years of total ixekizumab exposure) as of the March 19, 2021 database lock, the incidence rate for allergic reactions/hypersensitivities was 5.6 per 100 patient-years of exposure. These trials reported no confirmed events of anaphylaxis.5

IXORA-PEDS: Allergic Reaction/Hypersensitivity Treatment-Emergent Adverse Events in the Double-Blind Treatment Period and Combined Treatment Periods4

 

12-Week Double-Blind Treatment Period

Combined Treatment Periods
Through Week 108a 

 

Placebo
(N=56)
n (%)

Ixekizumab Q4W
(N=115)
n (%)

Total Ixekizumab
(N=196)
n (%)

Urticaria

0

2 (1.7)

5 (2.6)

Bronchospasm

0

1 (0.9)

1 (0.5)

Dermatitis atopic

0

1 (0.9)

5 (2.6)

Eczema

0

1 (0.9)

2 (1.0)

Rash maculopapular

0

1 (0.9)

1 (0.5)

Rash pustular

1 (1.8)

0

0

Dermatitis

0

0

2 (1.0)

Drug eruption

0

0

1 (0.5)

Eye edema

0

0

1 (0.5)

Injection-related reaction

0

0

1 (0.5)

Rash

0

0

1 (0.5)

Skin reaction

0

0

1 (0.5)

Swelling of eyelid

0

0

1 (0.5)

Abbreviation: Q4W = every 4 weeks.

aAll patients who received at least 1 dose of ixekizumab in the induction, maintenance, and extension periods through the 108-week final database lock (342.81 total patient-years of exposure), including patients switched to ixekizumab from placebo or etanercept following the double-blind induction treatment period.

Enclosed Prescribing Information

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1Paller AS, Seyger MMB, Magariños GA, et al; IXORA-PEDS Study Group. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231-241. https://doi.org/10.1111/bjd.19147

2Paller AS, Seyger MMB, Magariños GA, et al; IXORA-PEDS Investigators. Long-term efficacy and safety of up to 108 weeks of ixekizumab in pediatric patients with moderate to severe plaque psoriasis: the IXORA-PEDS randomized clinical trial. JAMA Dermatol. Published online April 13, 2022. https://dx.doi.org/10.1001/jamadermatol.2022.0655

3Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

4Data on file, Eli Lilly and Company and/or one of its subsidiaries.

5Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Poster presented at: Annual Meeting of the American Academy of Dermatology (AAD); March 25-29, 2022; Boston, MA.

Date of Last Review: April 29, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.4 08/2022 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2022. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    Facebook Twitter
    visit www.phactmi.org
    Lilly